New Therapies of Thyroid Diseases
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".
Deadline for manuscript submissions: closed (30 March 2022) | Viewed by 3237
Special Issue Editor
Special Issue Information
Dear Colleagues,
Classical treatment of thyroid cancers (TCs) based on surgery combined with radioiodine treatment in high-risk cases, is highly effective in differentiated TC (>98% of 10-years OS). Increasing evidence indicates that in spite of being effective in most of differentiated cancers, the current management is inadequate in approximately 50% of patients with medullary TC and radioiodine refractory advanced non-medullary TC, and in almost all patients with anaplastic TC. In recent years, the knowledge of molecular biology has improved which effected in new targeted drugs. In parallel, we observed development of diagnostic techniques including high quality, real time US, and FNA with molecular analysis profiling. Increasing evidence also indicates that a large part of the patients could be cured with de-escalated treatment’s intensity and even watchful waiting was proposed for microcarcinoma’s. Optimizing the intensity of the treatment requires data considering survival, preoperative diagnostics including preoperative molecular profile of the tumor, and adequate surgery and postoperative targeted treatment. Additionally, it should consider the individual values and preferences of the patients that need to be explored and communicated between patients to physicians to ensure adequate shared-decision making. The concept of such a precision therapy, changing classical paradigm of TC requires a multidisciplinary approach and a close collaboration with patients.
In the collection of articles entitled “Precision therapy of thyroid cancer” we would like to present original papers, reviews and minireviews on thyroid cancer biology, its liaison with diagnostics therapy (precision surgery and radioiodine treatment), targeted therapy (genotyping of the cancer) and shared-decision making.
Prof. Dr. Marek Dedecjus
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Thyroid cancer
- precision therapy
- genotyping
- share-decision making
